{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Genelux Corp. overvalued or undervalued?
As of November 14, 2023, Genelux Corp. is considered overvalued and does not qualify for investment due to negative financial metrics, including a P/E ratio of -3.8576, despite a strong one-year stock return of 34.47%.
Is Genelux Corp. technically bullish or bearish?
As of June 2, 2025, the technical trend is mildly bearish due to daily moving averages and weekly KST indicating bearish momentum, despite a mildly bullish MACD and Dow Theory, suggesting caution amid mixed performance signals.
What does Genelux Corp. do?
Genelux Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $7 million and a market cap of $115.27 million. It has no dividend yield and negative key financial metrics, including a return on equity of -100.12%.
How big is Genelux Corp.?
As of Jun 18, Genelux Corp. has a market capitalization of 115.27 million, with net sales of 0.00 million and a net profit of -29.52 million over the latest four quarters. Shareholder's funds are 26.27 million, and total assets are 34.72 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
